Viewpoint: a response to “Screening and isolation to control methicillin-resistant Staphylococcus aureus: sense, nonsense, and evidence”

Antimicrobial Resistance and Infection Control

Daniel M Saman³  Lindsay E Calderon¹  Kevin T Kavanagh² 

[1]Eastern Kentucky University, Richmond, KY, USA

[2]Health Watch USA, 3396 Woodhaven Dr, Somerset 42503, KY, USA

[3]Essentia Institute of Rural Health, Duluth, MN, USA

关键词: CLABSI;    MRSA;    Active detection and isolation;    Research integrity;    Chlorhexidine;    ADI;    Surveillance;    Methicillin-resistant staphylococcus aureus;   

Others  :  1138331
DOI  :  10.1186/s13756-015-0044-9

 received in 2014-09-28, accepted in 2015-01-09,  发布年份 2015

【 摘 要 】

Surveillance and isolation for the prevention of methicillin-resistant Staphylococcus aureus (MRSA) has become a controversial topic, one that causes heated debate and appears to be surrounded by both politics and industrial conflicts-of-interest. There have been calls from numerous authors for a movement away from rigid mandates and toward an evidence-based medicine approach. However, much of the evidence can be viewed with an entirely different interpretation. Two major studies with negative findings have had an adverse impact on recommendations regarding active detection and isolation (ADI) for MRSA. However the negative findings in these studies can be explained by shortcomings in study implementation rather than the ineffectiveness of ADI. The use of daily chlorhexidine bathing has also been proposed as an alternative to ADI in ICU settings. There are shortcomings regarding the evidence in the literature concerning the effectiveness of daily chlorhexidine bathing. One of the major concerns with universal daily chlorhexidine bathing is the development of bacterial resistance. The use of surveillance and isolation to address epidemics and common dangerous pathogens should solely depend upon surveillance and isolation’s ability to prevent further spread to and infection of other patients through indirect contact. At present, there is a preponderance of evidence in the literature to support continuing use of surveillance and isolation to prevent the spread of MRSA.

【 授权许可】

   
2015 Kavanagh et al.; licensee BioMed Central.

【 参考文献 】

• [1]Fätkenheuer G, Hirschel B, Harbarth S. Screening and isolation to control meticillin-resistant Staphylococcus aureus: sense, nonsense, and evidence. Lancet. 2014 Aug 20. doi:10.1016/S0140-6736(14)60660-7. [Epub ahead of print]
• [2]Kavanagh KT1, Cimiotti JP, Abusalem S, Coty MB. Moving healthcare quality forward with nursing-sensitive value-based purchasing. J Nurs Scholarsh. 2012;44(4):385–95. doi:10.1111/j.1547-5069.2012.01469.x. Epub 2012 Oct 15.
• [3]Kavanagh KT, Saman DM, Yu Y: A perspective on how the United States fell behind Northern Europe in the Battle against Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother 2013, 57(12):5789-5791. doi:10.1128/AAC.01839-13. Epub 2013 Oct 7
• [4]Harbarth S, Fankhauser C, Schrenzel J, Christenson J, Gervaz P, Bandiera-Clerc C, et al.: Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 2008, 299(10):1149-1157. doi:10.1001/jama.299.10.1149
• [5]Huskins WC, Huckabee CM, O'Grady NP, Murray P, Kopetskie H, Zimmer L, et al.: Intervention to reduce transmission of resistant bacteria in intensive care. N Engl J Med 2011, 364(15):1407-1418. doi:10.1056/NEJMoa1000373
• [6]Kavanagh K, Abusalem S, Saman DM: A perspective on the evidence regarding methicillin-resistant Staphylococcus aureus surveillance. J Patient Saf 2012, 8(3):140-143. doi:10.1097/PTS.0b013e3182627b89
• [7]Kavanagh KT, Calderon LE, Saman DM, Abusalem SK. The use of surveillance and preventative measures for methicillin-resistant staphylococcus aureus infections in surgical patients. Antimicrob Resist Infect Control. 2014;3:18. doi:10.1186/2047-2994-3-18. eCollection 2014. Review.
• [8]Huang SS, Septimus E, Kleinman K, Moody J, Hickok J, Avery TR, et al.: Targeted versus universal decolonization to prevent ICU infection. N Engl J Med 2013, 368(24):2255-2265. doi:10.1056/NEJMoa1207290. Epub 2013 May 29
• [9]Derde LP, Cooper BS, Goossens H, Malhotra-Kumar S, Willems RJ, Gniadkowski M, et al.: Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. Lancet Infect Dis 2014, 14(1):31-39. doi:10.1016/S1473-3099(13)70295-0. Epub 2013 Oct 23
• [10]O’Reilly KB, Doubt cast on effectiveness of universal MRSA screening. AMA News. April 26, 2011 Retrieved on Aug. 30, 2014 From: http://www.amednews.com/article/20110426/profession/304269997/8/.
• [11]Robicsek A, Beaumont JL, Paule SM, Hacek DM, Thomson RB Jr, Kaul KL, et al.: Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med 2008, 148(6):409-418.
• [12]Rodríguez-Baño J, García L, Ramírez E, Lupión C, Muniain MA, Velasco C, et al.: Long-term control of endemic hospital-wide methicillin-resistant Staphylococcus aureus (MRSA): the impact of targeted active surveillance for MRSA in patients and healthcare workers. Infect Control Hosp Epidemiol 2010, 31(8):786-795. doi:10.1086/654003
• [13]Lee AS, Cooper BS, Malhotra-Kumar S, Chalfine A, Daikos GL, Fankhauser C, et al.: Comparison of strategies to reduce meticillin-resistant Staphylococcus aureus rates in surgical patients: a controlled multicentre intervention trial. BMJ Open 2010, 3(9):e003126. doi:10.1136/bmjopen-2013-003126
• [14]Jain R, Kralovic SM, Evans ME, Ambrose M, Simbartl LA, Obrosky DS, et al. Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections. N Engl J Med. 201;364(15):1419–30. doi:10.1056/NEJMoa1007474.
• [15]Evans ME, Kralovic SM, Simbartl LA, Freyberg RW, Obrosky DS, Roselle GA, et al.: Nationwide reduction of health care-associated methicillin-resistant Staphylococcus aureus infections in Veterans Affairs long-term care facilities. Am J Infect Control 2014, 42(1):60-62. doi:10.1016/j.ajic.2013.06.004
• [16]Edmond MB, Wenzel RP: Screening Inpatients for MRSA - Case Closed. N Engl J Med 2013, 368(24):2314-2315.
• [17]Rotter ML, Larsen SO, Cooke EM, Dankert J, Daschner F, Greco D, et al.: A comparison of the effects of preoperative whole-body bathing with detergent alone and with detergent containing chlorhexidine gluconate on the frequency of wound infections after clean surgery. The European Working Party on Control of Hospital Infections. J Hosp Infect 1988, 11:310-320.
• [18]Climo MW, Yokoe DS, Warren DK, Perl TM, Bolon M, Herwaldt LA, Weinstein RA, et al.: Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med 2013, 368(6):533-542. doi:10.1056/NEJMoa1113849
• [19]Maiwald M, Chan ES: Pitfalls in evidence assessment: the case of chlorhexidine and alcohol in skin antisepsis. J Antimicrob Chemother 2014, 69(8):2017-2021. doi:10.1093/jac/dku121. Epub 2014 Apr 28
• [20]Center for Disease Dynamics, Economics & Policy. First reported cases of bacterial resistance against key antibiotics. Accessed March 25, 2014. Available at http://cddep.org/tool/first_reported_cases_bacterial_resistance_against_key_antibiotics.
• [21]Suwantarat N, Carroll KC, Tekle T, Ross T, Maragakis LL, Cosgrove SE, et al. High prevalence of reduced chlorhexidine susceptibility in organisms causing central line-associated bloodstream infections. Infect Control Hosp Epidemiol. 2014;35(9):1183–6. V
• [22]Lee AS, Macedo-Vinas M, François P, Renzi G, Schrenzel J, Vernaz N, et al.: Impact of combined low-level mupirocin and genotypic chlorhexidine resistance on persistent methicillin-resistant Staphylococcus aureus carriage after decolonization therapy: a case–control study. Clin Infect Dis 2011, 52(12):1422-1430.
• [23]Allen M. Hidden Financial Ties Rattle Top Health Quality Group. Jan. 28, 2014. Accessed on Aug. 13, 2014 from http://www.propublica.org/article/hidden-financial-ties-rattle-top-health-quality-group.
• [24]Sullivan S. CareFusion Settlement Features Corporate Regulatory Officer as Whistle Blower, Implicating High Profile Physicians. Policy and Medicine. Feb. 11, 2014. Accessed on Aug. 31, 2014 from http://www.policymed.com/2014/02/care-fusion-settlement-features-corporate-regulatory-officer-as-whistle-blower-implicating-high-profile-physicians.html.
• [25]Darouiche RO, Wall MJ Jr, Itani KM, Otterson MF, Webb AL, Carrick MM, et al.: Chlorhexidine-Alcohol versus Povidone-Iodine for Surgical-Site Antisepsis. N Engl J Med 2010, 362(1):18-26. doi:10.1056/NEJMoa0810988
• [26]Johnson B. Influential patient safety board cut ties with doc before CareFusion kickbacks case. Mass Device. Jan. 22, 2014. Accessed on Aug. 31, 2014 from http://www.massdevice.com/news/influential-patient-safety-board-cut-ties-with-doc-carefusion-kickbacks-case.
• [27]CareFusion to Pay the Government $40.1 Million to Resolve Allegations That Include More Than $11 Million in Kickbacks to One Doctor Department of Justice. Civil Division. Jan. 9, 2014. Accessed on Aug. 31, 2014 from http://www.justice.gov/opa/pr/2014/January/14-civ-021.html.
• [28]Wu AW, Kavanagh KT, Pronovost PJ, Bates DW: Conflict of interest, dr charles denham and the journal of patient safety. J Patient Saf 2014, 10(4):181-185.
• [29]ClinicalTrails.gov Archive. Changes to NCT00980980 on 2012_06_19. Jun. 19, 2013. Last accessed on Aug. 31. 2014 from: http://clinicaltrials.gov/archive/NCT00980980/2012_06_19/changes.
• [30]Huang SS, Platt R. Planned Analyses of the REDUCE MRSA Trial. Antimicrob Agents Chemother. 2014;58(4):2485. doi:10.1128/AAC. 02792–13.
• [31]Kavanagh KT, Saman DM, Yu Y. Reply to "Planned analyses of the REDUCE MRSA Trial". Antimicrob Agents Chemother. 2014;58(4):2486–7. doi:10.1128/AAC. 02821–13.
• [32]ClinicalTrails.gov Archive. Changes to NCT00980980 on 2013_10_16. Jun. 19, 2013. Last accessed on Aug. 31. 2014 from: http://clinicaltrials.gov/archive/NCT00980980/2013_10_16/changes.
• [33]Neely AN, Maley MP: Survival of enterococci and staphylococci on hospital fabrics and plastic. J Clin Microbiol 2000, 38(2):724-726.
• [34]Chang S, Sethi AK, Stiefel U, Cadnum JL, Donskey CJ: Occurrence of skin and environmental contamination with methicillin-resistant Staphylococcus aureus before results of polymerase chain reaction at hospital admission become available. Infect Control Hosp Epidemiol 2010, 31(6):607-612. doi:10.1086/652775
• [35]Knelson LP, Williams DA, Gergen MF, Rutala WA, Weber DJ, Sexton DJ, et al.: A comparison of environmental contamination by patients infected or colonized with methicillin-resistant Staphylococcus aureus or vancomycinresistant enterococci: a multicenter study. Infect Control Hosp Epidemiol 2014, 35(7):872-875. doi:10.1086/676861. Epub 2014 May 7
• [36]Siegel JD, Rhinehart E, Jackson M, Chiarello L Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. Healthcare Infection Control Practices Advisory Committee, Center for Disease Control and Prevention, June 2007. Last access on Nov. 15, 2014 from http://www.cdc.gov/hicpac/pdf/isolation/isolation2007.pdf.
• [37]Edmond MB, Diekema DJ, Perencevich EN. Ebola Virus Disease and the Need for New Personal Protective Equipment. JAMA. 2014 Oct 28. doi:10.1001/jama.2014.15497. [Epub ahead of print]
• [38]Grifo F, Halpern M, Hansel P. Heads they win, tails we lose. Union of Concerned Scientists. Feb. 2012. Accessed on Sep. 1, 2014 from: http://www.ucsusa.org/assets/documents/scientific_integrity/how-corporations-corrupt-science.pdf.